Brilique 90 mg orodispersible tablets
Authorisation EU/1/10/655/012-014 · AstraZeneca AB
- Licence holder
- AstraZeneca AB (all products →)
- Active substance
- Ticagrelor
- Clinical trials
- 30 clinical trials →
- Dosage form
- Orodispersible tablet
- Route of administration
- Oral use
- ATC code
- B01AC24
- First authorised
- 18/05/2017
- Prescription status
- Product subject to prescription which may be renewed (B)
- Supply
- Supply through pharmacies only
- Legal basis
- New active substance (Article 8(3) of Directive No 2001/83/EC)
Ticagrelor: supply and approvals
14 authorised products on the HPRA list contain Ticagrelor. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.
- EU shortage (EMA)
- No entry in the EMA shortage catalogue (checked 18 Nov 2026)
- US shortage (FDA)
- No entry in the FDA drug shortage list (checked 18 Nov 2026)
- Germany (BfArM)
- No entry in the BfArM supply notices (checked 18 Nov 2026)
Registers: EU shortages · US shortages · German shortages · EMA approvals
About this licence
Centralised EU authorisation. This product holds an EU-wide marketing authorisation granted by the European Commission after assessment by the European Medicines Agency, valid in every EU country. Its EU product number is 655. It has been authorised for 9 years (since 18 May 2017). The HPRA list does not say whether it is on sale.
Other medicines with Ticagrelor in Ireland
13 other products on the HPRA list contain Ticagrelor, from 8 licence holders; 3 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.
| Medicine | Licence holder | Licence | Status |
|---|---|---|---|
| Ticagrelor Krka 90 mg film-coated tablets | KRKA, d.d., Novo mesto | National authorisation (PA) | Marketed |
| Ticagrelor Rowex 90 mg Film-coated tablets | Rowex Limited, | National authorisation (PA) | Marketed |
| Ticagrelor Teva 90 mg Film-coated Tablets | Teva B.V. | National authorisation (PA) | Marketed |
| Brilique 60 mg film-coated tablets | AstraZeneca AB | Centralised EU authorisation | Not stated |
| Brilique 90 mg film-coated tablets | AstraZeneca AB | Centralised EU authorisation | Not stated |
| Ticagrelor Accord 60 mg film-coated tablets | Accord Healthcare Ireland Ltd. | National authorisation (PA) | Not marketed |
| Ticagrelor Accord 90 mg film-coated tablets | Accord Healthcare Ireland Ltd. | National authorisation (PA) | Not marketed |
| Ticagrelor Bluefish 60 mg film-coated tablets | Bluefish Pharmaceuticals AB | National authorisation (PA) | Not marketed |
| Ticagrelor Bluefish 90 mg film-coated tablets | Bluefish Pharmaceuticals AB | National authorisation (PA) | Not marketed |
| Ticagrelor Krka 60 mg film-coated tablets | KRKA, d.d., Novo mesto | National authorisation (PA) | Not marketed |
| Ticagrelor MSN 60 mg film-coated tablets | MSN Labs Europe Limited | National authorisation (PA) | Not marketed |
| Ticagrelor MSN 90 mg film-coated tablets | MSN Labs Europe Limited | National authorisation (PA) | Not marketed |
The licence holder
AstraZeneca AB holds 69 products on the HPRA list, with 43 different active substances; 9 of the products are marked as marketed.
This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.
How this page is built
The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.
- HPRA Authorised Medicines List (open data) ↗ Licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status for this product
This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 19 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.